Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doxil + carboplatin
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
Doxil + carboplatin is a combination chemotherapy regimen consisting of intravenous pegylated liposomal doxorubicin (Doxil) and intraperitoneal carboplatin. This specific combination and route of administration (IV/IP) was investigated by the University of Texas Southwestern Medical Center as a salvage therapy for patients with platinum-sensitive recurrent ovarian cancer. Doxorubicin is an anthracycline that works by intercalating DNA and inhibiting topoisomerase II, while carboplatin is a platinum-based antineoplastic agent that causes DNA cross-linking, collectively inhibiting DNA synthesis and cell division in tumor cells. The liposomal formulation of doxorubicin (Doxil) is designed to improve the drug's pharmacokinetic profile and reduce cardiotoxicity compared to conventional doxorubicin.
- Brand names
- DoxilParaplatin
- Other names
- liposomal doxorubicin + carboplatindoxorubicin hydrochloride liposome + carboplatin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Doxil + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doxil + carboplatin.